share_log

Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $48

Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $48

Baird维持对ptc therapeutics的跑赢市场评级,将目标股价上调至48美元
Benzinga ·  2024/11/08 20:29  · 评级/大行评级

Baird analyst Joel Beatty maintains PTC Therapeutics (NASDAQ:PTCT) with a Outperform and raises the price target from $44 to $48.

Baird分析师Joel Beatty维持对ptc therapeutics(纳斯达克:PTCT)的增长评级,并将价格目标从44美元提高至48美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发